Highlights

  • 4DMedical Limited (ASX:4DX) reported 119,672 scans in the September 2026 quarter.
  • Quarterly Operating Revenue reached AUD 2.3 million, according to the company.
  • Its software products were delivered across 724 sites globally.
  • September-quarter cash was AUD 242.8 million.

4DMedical Limited develops medical imaging software that analyses lung function using computed tomography and other imaging techniques. On November 17, 2026, its shares (ASX:4DX) traded at AUD 2.13, down 2.74% during the session. The company’s September-quarter update described higher scan volumes, a wider customer network and commercial activity in respiratory diagnostics, alongside its recently reported FY26 results.

Respiratory Imaging Products and Customers

The company offers software that derives functional lung information from clinical imaging. CT:VQ is designed to present ventilation and perfusion information, while CT LVAS measures regional lung ventilation using inspiratory and expiratory CT scans. These offerings target clinicians investigating respiratory disease and patients requiring more detailed assessment of lung function. Its commercial footprint includes U.S. health systems and Australian imaging providers. The software-oriented model depends on technical integration, clinical use and the number of scans processed, rather than only the installation of equipment.

September Quarter Brings Higher Scan Activity

In its October 2026 quarterly disclosure, 4DMedical (ASX:4DX) reported a record 119,672 scans for the three months ended September 30, an increase of 61% on the corresponding period. Its software was being delivered at 724 sites worldwide, representing growth of 34% sequentially and 77% year on year. Those figures describe adoption and usage, but do not directly establish profitability. The company also highlighted Australian CT:VQ agreements involving Jones Radiology, Qscan and providers within the Integral Diagnostics network.

The group disclosed a U.S. Veterans Affairs network agreement for its lung-density analysis software focused on chronic obstructive pulmonary disease detection. The five-year arrangement, structured around an initial year and potential annual extensions, has an estimated value of approximately US$800,000 over the full term. 4DMedical (ASX:4DX) also referred to progress in the CLEAR study, with a readout planned for calendar 2027, and work with the Vienna Business Agency relating to artificial-intelligence diagnostic deployment.

Financial Results and Cash Position

The September-quarter report placed unaudited operating revenue at AUD 2.3 million, up 66% compared with the corresponding quarter, and stated that gross margins exceeded 90%. Cash at September 30 stood at AUD 242.8 million. The FY26 results separately disclosed revenue from ordinary activities of approximately AUD 7.1 million, an increase of 21%, and a reported net loss of approximately AUD 204.4 million. A material non-cash financial-debt remeasurement affected the statutory outcome, making a distinction between accounting loss and operating activity important.

An adjusted net loss of approximately AUD 32.9 million was also disclosed for FY26. For 4DMedical (ASX:4DX), interpreting these results requires considering product revenue, ongoing expenditure and financing effects together. Software gross margins do not eliminate research, clinical-development, staffing or commercialisation costs. Continued spending may be needed to support broader hospital deployment and clinical evidence generation.

Execution Risks and What Comes Next

The commercial programme is exposed to hospital onboarding times, regulatory requirements, reimbursement arrangements, clinical adoption and competition from established imaging workflows. Agreements with headline multiyear values may translate into revenue gradually and can involve extension provisions. The company must also demonstrate that growing scan counts produce repeatable commercial receipts. Investors can monitor later quarterly revenue, utilisation at existing sites, cash expenditure, customer additions and progress on the CLEAR study.

Key Insights

4DMedical (ASX:4DX) entered the next reporting period with growing reported scan activity, new customer arrangements and a sizeable September cash balance. Its FY26 statutory loss, however, shows why commercial momentum and financial performance should be considered separately. Future disclosures on revenue conversion, clinical evidence, costs and deployments will help clarify the trajectory of the imaging business.